0001562180-24-000447.txt : 20240112 0001562180-24-000447.hdr.sgml : 20240112 20240112165715 ACCESSION NUMBER: 0001562180-24-000447 CONFORMED SUBMISSION TYPE: 3 PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20240104 FILED AS OF DATE: 20240112 DATE AS OF CHANGE: 20240112 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Leonard Frank X CENTRAL INDEX KEY: 0001822879 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 3 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37565 FILM NUMBER: 24532658 MAIL ADDRESS: STREET 1: 20 VALLEY STREAM PARKWAY, STREET 2: SUITE 300 CITY: MALVERN STATE: PA ZIP: 19355 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: NovoCure Ltd CENTRAL INDEX KEY: 0001645113 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] ORGANIZATION NAME: 08 Industrial Applications and Services IRS NUMBER: 000000000 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: NO. 4 THE FORUM STREET 2: GRENVILLE STREET CITY: ST. HELIER STATE: Y9 ZIP: JE2 4UF BUSINESS PHONE: 44 (0)15 3475 6700 MAIL ADDRESS: STREET 1: NO. 4 THE FORUM STREET 2: GRENVILLE STREET CITY: ST. HELIER STATE: Y9 ZIP: JE2 4UF FORMER COMPANY: FORMER CONFORMED NAME: Novocure Ltd DATE OF NAME CHANGE: 20150615 3 1 primarydocument.xml PRIMARY DOCUMENT X0206 3 2024-01-04 0 0001645113 NovoCure Ltd NVCR 0001822879 Leonard Frank X C/O NOVOCURE INC. 1550 LIBERTY RIDGE DRIVE, SUITE 115 WAYNE PA 19087 false true false false EVP, Pres., Novocure Oncology Ordinary Shares 45268.00 D Restricted Share Units 5791.00 D Restricted Share Units 2903.00 D Restricted Share Units 2277.00 D Restricted Share Units 6207.00 D Stock Options (Right to buy) 153.09 2024-03-02 2031-03-01 Ordinary Shares 16003.00 D Stock Options (Right to buy) 84.68 2024-09-01 2030-08-31 Ordinary Shares 11336.00 D Stock Options (Right to buy) 83.30 2029-07-30 Ordinary Shares 7809.00 D Stock Options (Right to buy) 80.59 2024-03-01 2032-02-29 Ordinary Shares 4933.00 D Stock Options (Right to buy) 80.59 2024-03-01 2032-02-29 Ordinary Shares 30422.00 D Stock Options (Right to buy) 76.97 2024-02-28 2033-02-27 Ordinary Shares 30971.00 D Stock Options (Right to buy) 73.20 2024-11-01 2032-10-31 Ordinary Shares 11609.00 D Stock Options (Right to buy) 69.37 2024-03-03 2030-03-02 Ordinary Shares 1441.00 D Stock Options (Right to buy) 69.37 2024-03-03 2030-03-02 Ordinary Shares 8981.00 D Stock Options (Right to buy) 47.04 2029-03-21 Ordinary Shares 14595.00 D Stock Options (Right to buy) 34.00 2028-07-30 Ordinary Shares 16148.00 D Stock Options (Right to buy) 21.15 2028-02-26 Ordinary Shares 10479.00 D Represents restricted share units that are scheduled to vest in equal installments on March 1, 2024 and 2025, subject to the reporting person's continued employment through such dates. Options to buy 30,971 ordinary shares will vest in equal installments on each of February 28, 2024, 2025, 2026 and 2027, subject to the reporting person's continued employment through such dates. Options to buy 11,609 ordinary shares, 2,903 shares of which are currently exercisable and the remainder will vest in equal installments on each of November 1, 2024, 2025 and 2026, subject to the reporting person's continued employment through such dates. Options to buy 10,422 ordinary shares, 7,817 shares of which are currently exercisable and the remainder will vest on March 2, 2024, subject to the reporting person's continued employment through such date. Represents restricted share units that are scheduled to vest on March 2, 2024, subject to the reporting person's continued employment through such date. Represents restricted share units that are scheduled to vest in equal installments on November 1, 2024 and 2025, subject to the reporting person's continued employment through such dates. Represents restricted share units that are scheduled to vest in equal installments on February 28, 2024, 2025 and 2026, subject to the reporting person's continued employment through such dates. Options to buy 16,003 ordinary shares, 8,002 shares of which are currently exercisable and the remainder will vest in equal installments on each of March 2, 2024 and 2025, subject to the reporting person's continued employment through such dates. Options to buy 11,336 ordinary shares, 8,502 shares of which are currently exercisable and the remainder will vest on September 1, 2024, subject to the reporting person's continued employment through such date. Currently exercisable. Options to buy 4,933 ordinary shares, 2,467 shares of which are currently exercisable and the remainder will vest on March 1, 2024, subject to the reporting person's continued employment through such date. Options to buy 30,422 ordinary shares, 7,606 shares of which are currently exercisable and the remainder will vest in equal installments on each of March 1, 2024, 2025 and 2026, subject to the reporting person's continued employment through such dates. Steven Robbins, as attorney in fact for Leonard, Frank X. 2024-01-12 EX-24 2 poa-ex24_leonard.txt EX-24 POA - FRANK X. LEONARD LIMITED POWER OF ATTORNEY FOR SECTION 16 REPORTING PURPOSES Know all by these presents, that the undersigned hereby makes, constitutes and appoints Barak Ben-Arye, Steven Robbins, Ovie Onobrakpeya and Carrie Kane, individually, as the undersigned's true and lawful attorneys-in-fact, with full power and authority as hereinafter described on behalf of and in the name, place and stead of the undersigned to: (1) execute for, and on behalf of, the undersigned, in the undersigned's capacity as an officer, director and/or 10% beneficial owner of Novocure Limited (the "Company"), Forms 3, 4, and 5 in accordance with Section 16(a) of the Securities Exchange Act of 1934 and the rules and regulations promulgated thereunder (the "Exchange Act"); (2) seek or obtain, as the undersigned's representative and on the undersigned's behalf, information on transactions in the Company's securities from any third party, including brokers, employee benefit plan administrators and trustees, and the undersigned hereby authorizes any such person to release any such information to any attorneys-in-fact and further approves and ratifies any such release of information; (3) do and perform any and all acts for and on behalf of the undersigned that may be necessary or desirable to prepare, complete and execute any such Form 3, 4 or 5, and any amendments thereto, or other required report and timely file such Forms or reports with the United States Securities and Exchange Commission, the New York Stock Exchange and any stock exchange or similar authority as considered necessary or advisable under Section 16(a) of the Exchange Act; and (4) take any other action of any type whatsoever in connection with the foregoing which, in the opinion of such attorneys-in- fact, may be of benefit to, in the best interest of, or legally required by, the undersigned, it being understood that the documents executed by such attorneys-in-fact on behalf of the undersigned pursuant to this Limited Power of Attorney shall be in such form and shall contain such terms and conditions as such attorneys-in-fact may approve in such attorney-in-fact's sole discretion. The undersigned hereby gives and grants to each such attorneys-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary, or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that such attorneys-in- fact, or such attorneys-in-fact's substitute or substitutes, shall lawfully do or cause to be done by virtue of this power of attorney and the rights and powers herein granted. The undersigned hereby acknowledges that (a) the foregoing attorneys-in-fact are serving in such capacity at the request of the undersigned; (b) this Limited Power of Attorney authorizes, but does not require, each such attorneys-in-fact to act in his or her discretion on information provided to such attorneys-in-fact without independent verification of such information; (c) any documents prepared and/or executed by any attorneys-in-fact on behalf of the undersigned pursuant to this Limited Power of Attorney shall be in such form and shall contain such information and disclosure as such attorneys-in-fact, in his or her sole discretion, deems necessary or advisable; (d) neither the Company nor any attorneys-in- fact assumes (i) any liability for the undersigned's responsibility to comply with the requirements of the Exchange Act, (ii) any liability of the undersigned for any failure to comply with such requirements or (iii) any obligation or liability of the undersigned for profit disgorgement under Section 16(b) of the Exchange Act; and (e) this Limited Power of Attorney does not relieve the undersigned from responsibility for compliance with the undersigned's obligations under the Exchange Act, including, without limitation, the reporting requirements under Section 16 of the Exchange Act. This Limited Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file Forms 3, 4, and 5 with respect to the undersigned's holdings of, and transactions in, securities issued by the Company, unless earlier revoked as to any attorneys-in-fact by the undersigned in a signed writing delivered to such attorneys-in-fact. IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of this 26th day of July, 2022. /s/ Frank X Leonard Signature Frank X Leonard Print Name